摘要
原发性肝癌是全球范围内最常见的恶性肿瘤之一,其发病率居所有恶性肿瘤的第6位,死亡率居第4位。原发性肝癌中90%以上的病例为肝细胞癌(以下简称肝癌)。近几年,随着各项临床研究的开展,肝癌的治疗模式由单一的局部治疗转变为多学科综合治疗模式。2021年5月,欧洲肿瘤内科学会在Annals of Oncology杂志发布了《2021年欧洲肿瘤内科学会肝细胞癌临床实践指南更新》。本文将对指南的更新内容进行解读。
Primary liver cancer is one of the most common malignances worldwide.Its incidence ranks sixth,and its mortality ranks fourth.More than 90%of cases of primary liver cancer are hepatocellular carcinoma.In recent years,with the development of various clinical studies,the treatment modality of hepatocellular carcinoma has changed from a single locoregional therapy to a multidisciplinary treatment.In May 2021,the European Society for Medical Oncology(ESMO)published Updated treatment recommendations for hepatocellular carcinoma(HCC)from the ESMO Clinical Practice Guidelines in Annals of Oncology.This article will interpret the updated content accordingly.
作者
张德耀
陈敏山
Zhang Deyao;Chen Minshan(Department of Liver Surgery,Sun Yat-sen University Cancer Center,State Key Laboratory of Oncology in South China,Collaborative Innovation Center for Cancer Medicine,Guangzhou 510060,China)
出处
《中国医学前沿杂志（电子版）》
2021年第8期1-4,共4页
Chinese Journal of the Frontiers of Medical Science(Electronic Version)
基金
国家自然科学基金面上项目(81874070)。
关键词
原发性肝癌
肝细胞癌
免疫治疗
进展
Primary liver cancer
Hepatocellular carcinoma
Immunotherapy
Progress
